文献速递造血干细胞移植与细胞治疗血栓与止血

LAWS评分预测异基因造血干细胞移植后颅内出血死亡风险

Predicting mortality from intracranial hemorrhage in patients who undergo allogeneic hematopoietic stem cell transplantation.
PubMed 文献 · Blood Adv · 2021-01-01

多因素logistic回归保留乳酸脱氢酶、白蛋白、白细胞计数和疾病状态4个预测因子,构建简化LAWS评分,两队列校准良好,区分度分别为C-statistic 0.859(95%CI 0.776-0.945)和0.795(95%CI 0.645-0.945)。

要点

  • LAWS评分是首个预测allo-HSCT患者ICH后30天死亡率的评分系统
  • LAWS评分在衍生队列C-statistic为0.859,外部验证队列为0.795
  • LAWS评分可用于对allo-HSCT合并ICH患者进行风险分层

核心结论

  • LAWS评分是首个能够预测allo-HSCT患者ICH后30天死亡率的评分系统。
  • 该评分在识别ICH诊断后早期死亡风险升高的allo-HSCT患者方面表现良好。

研究设计与样本

  • 研究为评分系统开发与外部验证研究。
  • 衍生队列为2008年1月至2020年6月共70例allo-HSCT后诊断ICH的患者。

主要发现

  • 多因素logistic回归模型保留乳酸脱氢酶水平、白蛋白水平、白细胞计数和疾病状态4个预测因子,并据此开发简化LAWS评分。
  • LAWS评分在两个队列中校准充分(Hosmer-Lemeshow检验,P > .05)。
  • 衍生队列区分度C-statistic为0.859(95%CI 0.776-0.945),外部验证队列为0.795(95%CI 0.645-0.945)。

关键数值与推荐

  • LAWS评分包含乳酸脱氢酶水平、白蛋白水平、白细胞计数和疾病状态4个预测因子。
  • 预测目标为allo-HSCT患者ICH诊断后30天死亡率。
  • 校准评估采用Hosmer-Lemeshow检验,两队列P > .05。
  • 区分度以C-statistic评价,衍生队列0.859(95%CI 0.776-0.945),外部验证队列0.795(95%CI 0.645-0.945)。

临床怎么用

  • 可依据LAWS评分对allo-HSCT合并ICH患者进行风险分层。
  • 该评分有助于未来针对不同LAWS风险组开发个体化及新型干预研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Intracranial hemorrhage (ICH) is a rare but fatal central nervous system complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, factors that are predictive of early mortality in patients who develop ICH after undergoing allo-HSCT have not been systemically investigated. From January 2008 to June 2020, a total of 70 allo-HSCT patients with an ICH diagnosis formed the derivation cohort. Forty-one allo-HSCT patients with an ICH diagnosis were collected from 12 other medical centers during the same period, and they comprised the external validation cohort. These 2 cohorts were used to develop and validate a grading scale that enables the prediction of 30-day mortality from ICH in all-HSCT patients. Four predictors (lactate dehydrogenase level, albumin level, white blood cell count, and disease status) were retained in the multivariable logistic regression model, and a simplified grading scale (termed the LAWS score) was developed. The LAWS score was adequately calibrated (Hosmer-Lemeshow test, P > .05) in both cohorts. It had good discrimination power in both the derivation cohort (C-statistic, 0.859; 95% confidence interval, 0.776-0.945) and the external validation cohort (C-statistic, 0.795; 95% confidence interval, 0.645-0.945). The LAWS score is the first scoring system capable of predicting 30-day mortality from ICH in allo-HSCT patients. It showed good performance in identifying allo-HSCT patients at increased risk of early mortality after ICH diagnosis. We anticipate that it would help risk stratify allo-HSCT patients with ICH and facilitate future studies on developing individualized and novel interventions for patients within different LAWS risk groups.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ren X, Huang Q, Qu Q, et al. Predicting mortality from intracranial hemorrhage in patients who undergo allogeneic hematopoietic stem cell transplantation. Blood Adv. 2021. PMID: 34448835. doi:10.1182/bloodadvances.2021004349

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。